The word dementia describes a class of heterogeneous diseases which etiopathogenetic mechanisms are not well understood. There are different types of dementia, among which, Alzheimer’s disease (AD), vascular dementia (VaD),…
Condition: Alzheimer’s Dementia
Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia
Rationale: Nighttime agitation occurs frequently in patients with dementia and represents the number one burden on caregivers today. Current treatment options are few and limited due to substantial side effects….
Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic
The limited effectiveness of current therapies against Alzheimer’s disease (AD) highlights the need for intensifying research efforts devoted to developing new agents for preventing or retarding the disease process. During…
Cannabinoids for the treatment of dementia
Following the discovery of an endogenous cannabinoid system and the identification of specific cannabinoid receptors in the central nervous system, much work has been done to investigate the main effects…
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Objective: The aim of this review is to describe the historical development of research on cannabidiol. Method: This review was carried out on reports drawn from Medline, Web of Science…
Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer’s disease
Microglial activation is an invariant feature of Alzheimer’s disease (AD). It is noteworthy that cannabinoids are neuroprotective by preventing β-amyloid (Aβ)-induced microglial activation both in vitro and in vivo. On…
Amyloid-beta inhibits E-S Potentiation through suppression of cannabinoid receptor 1 dependent synaptic disinhibition
Objective: The management of agitation in dementia is a growing problem and conventional modes of intervention have limited efficacy. Synthetic Cannabinoids have been studied in other conditions like pain and…